Metastases to biliary tract

1 trials 1 recruiting MedDRA PT
1 Registered trials
1 Recruiting
1 Unique sponsors
6 Unique IMPs
1 Commercial trials
Drug classes (ATC)
L Oncology (ATC L) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 2 substances
Antibody-drug conjugate (ADC) 2 substances
PARP inhibitor 1 substance
Alkylating agent 1 substance
Phase I (First in Human): 1

Filter these 1 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 1 trials

Phase I (First in Human)

1 trial
  • AstraZeneca AB Commercial
    [11C]AZ14193391; 6-FLUORO-5-[4-[(5-FLUORO-2-METHYL-3-OXO-4H-QUINOXALIN-6-YL)METHYL]PIPERAZIN-1-YL]-N-METHYLPYRIDINE-2-CARBOXAMIDE; DATOPOTAMAB DERUXTECAN; PALACAPARIB; TEMOZOLOMIDE; TRASTUZUMAB DERUXTECAN
    2023-504984-17-00 2 countries 2022 n=176
    Recruiting
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
AstraZeneca AB Commercial 1 Phase I (First in Human) 1
New trials by year
2022
1
← All indication landscapes